EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Potent Non-Peptide Thrombin Receptor Antagonists

Samuel Chackalamannil, Ho-Sam Ahn, Yan Xia, Darío Doller, Carolyn Foster

Current Medicinal Chemistry-Cardiovascular & Hematological Agents · 2003

DOI: 10.2174/1568016033356706 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Medicinal Chemistry-Cardiovascular & Hematological Agents, 2003. Verfasst von Samuel Chackalamannil und 4 weiteren Autor:innen. Beteiligte Einrichtung: Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. samuel.chackalamannil@spcorp.com. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 8-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Protease activated receptor-1 (PAR-1), also known as thrombin receptor, is present in a variety of cell types such as platelets and endothelial cells. PAR-1 is proteolytically activated by thrombin by cleavage at its extracellular domain, unmasking a new amino terminus, which internally binds to the proximal receptor, eliciting cellular activation. Inhibition of the cellular activation by thrombin is a potentially promising therapeutic approach for the treatment of thrombotic and vascular proliferative disorders such as atherosclerosis and restenosis. Reported herein is the pharmacology of potent, low molecular weight thrombin receptor antagonists from pyrroloquinazoline, benzimidazole, and himbacine series. In the radioligand binding assay, these compounds inhibited PAR-1 in a competitive manner. They also inhibited thrombin and agonist peptide induced human platelet aggregation in a dose-dependent manner. Additionally, these compounds showed dose-dependent inhibition of agonist-induced cytosolic Ca(+2) transients and thymidine incorporation in human coronary artery smooth muscle cells (hCASMC). The most potent compound among these antagonists showed a Ki of 12 nM in the radioligand binding assay and an IC50 of 70 nM in the platelet aggregation inhibition assay.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet Aggregation InhibitorsDrug DesignHeterocyclic CompoundsHumansInhibitory Concentration 50Structure-Activity Relationship

Substanzen

Heterocyclic CompoundsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. samuel.chackalamannil@spcorp.com

Zitieren

APA

Chackalamannil, S., Ahn, H. S., Xia, Y., Doller, D., & Foster, C. (2003). Potent Non-Peptide Thrombin Receptor Antagonists. Current Medicinal Chemistry-Cardiovascular & Hematological Agents. https://doi.org/10.2174/1568016033356706

Vancouver

Chackalamannil S, Ahn HS, Xia Y, Doller D, Foster C. Potent Non-Peptide Thrombin Receptor Antagonists. Current Medicinal Chemistry-Cardiovascular & Hematological Agents. 2003. doi:10.2174/1568016033356706

BibTeX
@article{Chackalamannil2003,
  author = {Chackalamannil, Samuel and Ahn, Ho-Sam and Xia, Yan and Doller, Darío and Foster, Carolyn},
  title = {Potent Non-Peptide Thrombin Receptor Antagonists},
  journal = {Current Medicinal Chemistry-Cardiovascular & Hematological Agents},
  year = {2003},
  doi = {10.2174/1568016033356706}
}
Kostenlos starten →